Table 1.
Baseline characteristics of 29 new-onset and 48 eyes with chronic diabetic macular edema treated with brolucizumab or aflibercept.
| Brolucizumab | Aflibercept | |||
|---|---|---|---|---|
| Treatment-Naïve DME | Recalcitrant DME | Treatment -Naïve DME | Recalcitrant DME | |
| No. of eyes (patients) | 12 (8) | 23 (16) | 17 (13) | 23 (18) |
| Male/female | 6/2 | 11/5 | 9/4 | 13/5 |
| Age, years | 55.3 (±19) | 60.2 (±8) | 64.5 (±19) | 67.4 (±9) |
| Diabetic retinopathy, % | ||||
| Mild NPDR: | - | 9 | 12 | 11 |
| Moderate NPDR: | 8 | 9 | 12 | 5 |
| Severe NPDR: | 33 | 52 | 35 | 17 |
| PDR: | 59 | 30 | 41 | 67 |
| No. of eyes with prior vitrectomy | 0/12 | 1/23 | 0/17 | 1/23 |
| No. of eyes with prior PRP | 0/12 | 9/23 | 3/17 | 16/23 |
| No. of eyes with prior intravitreal | N/A | N/A | ||
| Bevacizumab | 21 | 15 | ||
| Ranibizumab | 9 | 16 | ||
| Aflibercept | 6 | N/A | ||
| Dexamethasone | 6 | 5 | ||
| BCVA (logMAR) | 0.31 ± 0.1 | 0.43 ± 0.3 | 0.48 ± 0.3 | 0.44 ± 0.2 |
| CRT, µm | 441.8 ± 50.9 | 447.1 ± 68.8 | 456.7 ± 141.5 | 422.4 ± 141.1 |
| Intraretinal fluid (%) | 100% | 100% | 100% | 100% |
| Subretinal fluid (%) | 0% | 0% | 17% | 26% |
BCVA = best-corrected visual acuity; CRT = central retinal thickness; logMAR = logarithm of minimal angle of resolution; N/A = not applicable; NPDR = non proliferative diabetic retinopathy; PDR = proliferative diabetic retinopathy.